Research
Hormonal
Semaglutide (2.4 mg weekly) induces significant weight loss (approx. 14.9%) in adults with obesity, superior to Liraglutide (3 mg daily) and placebo.
Semaglutide 2.4mg once weekly is a highly effective treatment for obesity, producing nearly 15% weight loss in clinical trials. It works by targeting brain pathways that control appetite. While it requires weekly injections, its efficacy is superior to older daily GLP-1 medications.
StrongSupportsVERY_HIGH confidence
Dopo 68 settimane, i soggetti in trattamento con semaglutide 2.4 mg ottenevano un decremento ponderale del 14,9% a confronto con il 2,4% del gruppo placebo... I benefici sul peso corporeo di semaglutide ad alto dosaggio sembrano essere superiori a quelli ottenibili con liraglutide 3 mg...
Why this rating
Based on Phase 3 STEP trials with large sample sizes.
Source
Terapia farmacologica dell’obesità: attualità e prospettive future
Federica Vinciguerra et al. · L Endocrinologo · 2022
DOI 10.1007/s40619-022-01068-7
narrative_reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide (5-15 mg weekly) produces dose-dependent weight loss (up to 11% in diabetics) and superior weight reduction compared to Semaglutide 1mg in patients with type 2 diabetes.Strong
- Orlistat (120 mg twice daily) produces a statistically significant weight reduction (>2.9% vs placebo) and improves cardiovascular risk factors in obese patients, including those with type 2 diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →